COVID ‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

Stručni rad - Stručni rad

• Autor: Giuseppe Rosano
• Autor: Ewa A. Jankowska
• Autor: Robin Ray
• Autor: Marco Metra
• Autor: Magdy Abdelhamid
• Autor: Stamatis Adamopoulos
• Autor: Stefan D. Anker
• Autor: Antoni Bayes‐Genis
• Autor: Yury Belenkov
• Autor: Tuvia B. Gal
• Autor: Michael Böhm
• Autor: Ovidiu Chioncel
• Autor: Alain Cohen‐Solal
• Autor: Dimitrios Farmakis
• Autor: Gerasimos Filippatos
• Autor: Arantxa González
• Autor: Finn Gustafsson
• Autor: Loreena Hill
• Autor: Tiny Jaarsma
• Autor: Fadi Jouhra
• Autor: Mitja Lainscak
• Autor: Ekaterini Lambrinou
• Autor: Yury Lopatin
• Autor: Lars H. Lund
• Autor: Davor Miličić
• Autor: Brenda Moura
• Autor: Wilfried Mullens
• Autor: Massimo F. Piepoli
• Autor: Piotr Ponikowski
• Autor: Amina Rakisheva
• Autor: Arsen Ristic
• Autor: Gianluigi Savarese
• Autor: Petar Seferovic
• Autor: Michele Senni
• Autor: Thomas Thum
• Autor: Carlo G. Tocchetti
• Autor: Sophie Van Linthout
• Autor: Maurizio Volterrani
• Autor: Andrew J.S. Coats
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA INTERNU MEDICINU)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina

Sažetak (engleski)

Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.

• Ključne riječi (engleski): Aged; COVID-19 Vaccines; COVID-19; Cardiology; Frail Elderly; Heart Failure; Humans; Iron Deficiencies; SARS-CoV-2; Vaccination
• Jezik: engleski
• Vrsta publikacije: Stručni rad - Stručni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: European Journal of Heart Failure
• Brojčani podaci: vol. 23, br. 11, str. 1806-1818
• p-ISSN: 1388-9842
• e-ISSN: 1879-0844
• DOI: https://doi.org/10.1002/ejhf.2356
• URN:NBN: urn:nbn:hr:105:077766
• Datum objave publikacije: 2021-12-05
• URL dokumenta: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2356
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2022-04-07 11:08:21